

Version 3.0 Revision Date: 13.11.2019 SDS Number: 13231 Date of last issue: 19.01.2018
Date of first issue: 19.01.2018

SECTION 1. PRODUCT AND COMPANY IDENTIFICATION

1.1 Product identifier

ATACAND PLUS TABLETS

Details of the supplier of the safety data sheet : ASTRAZENECA PTY LTD Emergency Telephone
PO Box 131 +44 (0) 1235 239 670
66 Talavera Rd, North Ryde
NSW 2113
AUSTRALIA
+61 2 9978 3500

SafetyDataSheets.AlderleyPark@astrazeneca.com

Alternative Names

Atacand HCT 8/12.5mg, 16/12.5mg, 32/12.5mg and 32/25mg
Candesartan Cilexetil and Hydrochlorothiazide tablets
CAS No. : Not applicable

1.2 Relevant identified uses of the substance or mixture and uses advised against


Use of the Substance/Mixture : antihypertensive agent

SECTION 2. HAZARDS IDENTIFICATION

GHS Classification

Reproductive toxicity : Category 1A
Specific target organ toxicity - repeated exposure (Oral) : Category 2 (Kidney, Blood)

GHS label elements

Hazard pictograms : 

Signal word : Danger

Hazard statements : H360 May damage fertility or the unborn child.
H373 May cause damage to organs (Kidney, Blood) through prolonged or repeated exposure if swallowed.

Precautionary statements : **Prevention:**
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P260 Do not breathe dust/ fume/ gas/ mist/ vapours/ spray.
P281 Use personal protective equipment as required.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/ attention.

Version 3.0 Revision Date: 13.11.2019 SDS Number: 13231 Date of last issue: 19.01.2018
Date of first issue: 19.01.2018

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

May cause lowering of blood pressure.

See Section 11.

The product may form flammable dust clouds in air, if dust from crushed tablets is allowed to accumulate.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Starch	9005-25-8	15.4
Candesartan Cilexetil	145040-37-5	6.1 -12.3
Hydrochlorothiazide	58-93-5	4.8 -9.6
Celluloses	9004-34-6	7.4
Magnesium stearate	557-04-0	0.3 -1

SECTION 4. FIRST AID MEASURES

- If inhaled : Remove patient from exposure.
Obtain medical attention if ill effects occur.
- In case of skin contact : Remove contaminated clothing.
Wash skin with soap and water.
If symptoms (irritation or blistering) occur obtain medical attention.
- In case of eye contact : Irrigate with eyewash solution or clean water, holding the eyelids apart, for at least 10 minutes.
Obtain medical attention.
- If swallowed : Wash out mouth with water and give 200-300ml of water to drink.
Do NOT induce vomiting as a First-Aid measure.
Obtain medical attention if ill effects occur.
- Most important symptoms and effects, both acute and delayed : Refer to sections 2 and 11
May damage fertility or the unborn child.
May cause damage to organs through prolonged or repeated exposure if swallowed.
- Notes to physician : Symptomatic treatment and supportive therapy as indicated.
For further detail consult the prescribing information.
-

SECTION 5. FIREFIGHTING MEASURES

Suitable extinguishing media : water spray, foam, dry powder or CO2.

Version 3.0 Revision Date: 13.11.2019 SDS Number: 13231 Date of last issue: 19.01.2018
Date of first issue: 19.01.2018

- Unsuitable extinguishing media : Avoid high pressure media which could cause the formation of a potentially explosible dust-air mixture.
- Specific hazards during firefighting : If involved in a fire, it may burn and emit noxious and toxic fumes.
- Special protective equipment for firefighters : A self contained breathing apparatus and suitable protective clothing should be worn in fire conditions.

SECTION 6. ACCIDENTAL RELEASE MEASURES

- Personal precautions, protective equipment and emergency procedures : Ensure suitable personal protection during removal of spillages.
Avoid dispersal of dust in the air.
See Section 8.
- Environmental precautions : Prevent entry into drains, sewers or watercourses.
- Methods and materials for containment and cleaning up : Transfer spilled tablets to a suitable container for disposal.
Wash the spillage area with water.

SECTION 7. HANDLING AND STORAGE

- Advice on safe handling : Avoid contact with skin and eyes.
Wash hands after use.
Minimize dust generation and accumulation.
The product may form flammable dust clouds in air, if dust from crushed tablets is allowed to accumulate.
- Conditions for safe storage : Keep container tightly closed and dry.
- Recommended storage temperature : < 30 °C

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Starch	9005-25-8	TWA	10 mg/m ³	AU OEL
	Further information: This value is for inhalable dust containing no asbestos and < 1% crystalline silica			
		TWA	10 mg/m ³	ACGIH
Candesartan Cilexetil	145040-37-5	TWA	0.001 mg/m ³	COM; HYG
Hydrochlorothiazide	58-93-5	TWA	0.5 mg/m ³	COM; HYG
Celluloses	9004-34-6	TWA	10 mg/m ³	AU OEL
	Further information: This value is for inhalable dust containing no asbestos and < 1% crystalline silica			
		TWA	10 mg/m ³	ACGIH
Magnesium stearate	557-04-0	TWA	10 mg/m ³	AU OEL

SAFETY DATA SHEET



Version 3.0 Revision Date: 13.11.2019 SDS Number: 13231 Date of last issue: 19.01.2018
 Date of first issue: 19.01.2018

	Further information: This value is for inhalable dust containing no asbestos and < 1% crystalline silica			
		TWA (Inhalable fraction)	10 mg/m ³	ACGIH
		TWA (Respirable fraction)	3 mg/m ³	ACGIH

Engineering measures : The specific controls will depend on local circumstances and should be based on the risk assessment. Appropriate controls to reduce exposure may include engineering controls, for example ventilation, procedural controls and the use of personal protection equipment.

Prevent entry into drains, sewers or watercourses.

Personal protective equipment

Respiratory protection : Use an air fed hood if the risk assessment does not support the selection of other protection.

Eye protection : Use safety glasses to protect against direct contact with the product if the risk assessment does not support the selection of other protection.

Skin and body protection : Use impervious clothing to protect against direct contact with the product or for repeated, excessive handling use full chemical protective suit if the risk assessment does not support the selection of other protection. Use impervious protective gloves to protect against direct contact with the product. If the product is dissolved or wetted use a glove material that is resistant to the solvent/liquid.

Protective measures : Decisions about whether the use of personal protective equipment (PPE) is appropriate as part of the control strategy should be based on the workplace risk assessment and should take account of local legislative requirements for selection and use. There are multiple factors that will affect the specific requirements such as amount and concentration of the material, duration of exposure, frequency of exposure, external environmental conditions, the task, the user etc. All the information above should not be used in isolation and should be considered in the context of the workplace risk assessment on a case by case basis.

The recommended personal protective equipment (PPE) is based on preventing the potential adverse health effects from exposure to the active pharmaceutical ingredient (API). The risk of exposure to the API in the formulation/product needs to be taken into consideration.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

SAFETY DATA SHEET



Version 3.0 Revision Date: 13.11.2019 SDS Number: 13231 Date of last issue: 19.01.2018
Date of first issue: 19.01.2018

Appearance : uncoated tablets

Colour : 8/12.5mg : white 16/12.5mg : peach 32/12.5mg :yellow
32/25 mg: light pink

Odour : No data available

Odour Threshold : No data available

pH : No data available

Melting point/range : No data available

Initial boiling point and boiling range : Not applicable

Flash point : Not applicable

Evaporation rate : Not applicable

Flammability (solid, gas) : No data available

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Vapour pressure : Not applicable

Relative vapour density : Not applicable

Relative density : No data available

Solubility(ies)
Water solubility : No data available
Solubility in other solvents : No data available

Partition coefficient: n-octanol/water : No data available

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity
Viscosity, dynamic : Not applicable
Viscosity, kinematic : Not applicable

Explosive properties : Not explosive

Version	Revision Date:	SDS Number:	Date of last issue: 19.01.2018
3.0	13.11.2019	13231	Date of first issue: 19.01.2018

Oxidizing properties : Not applicable

SECTION 10. STABILITY AND REACTIVITY

Reactivity : No known reactivity hazard under normal conditions.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : None known.

Conditions to avoid : No conditions producing hazardous situations known.

Incompatible materials : None known.

Hazardous decomposition products : No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

11.1 Acute toxicity

Not classified based on available information.

Components:

Candesartan Cilexetil:

Acute oral toxicity : LD50 Oral (Rat): > 2,000 mg/kg
Assessment: The substance or mixture has no acute oral toxicity

Acute inhalation toxicity : Remarks: No information available on acute toxicity.
May cause effects as described under single exposure.(STOT)

Acute dermal toxicity : Remarks: No information available.

Hydrochlorothiazide:

Acute oral toxicity : Remarks: Low acute oral toxicity.

Acute inhalation toxicity : Remarks: May cause effects as described under single exposure.(STOT)

Acute dermal toxicity : Remarks: No information available.

11.2 Skin corrosion/irritation

Not classified based on available information.

Components:

Candesartan Cilexetil:

Remarks : No evidence of irritant effects from normal handling and use.

Hydrochlorothiazide:

Version	Revision Date:	SDS Number:	Date of last issue: 19.01.2018
3.0	13.11.2019	13231	Date of first issue: 19.01.2018

Remarks : Unlikely to cause skin irritation.

11.3 Serious eye damage/eye irritation

Not classified based on available information.

Components:

Candesartan Cilexetil:

Remarks : No evidence of irritant effects from normal handling and use.

Hydrochlorothiazide:

Remarks : No evidence of irritant effects from normal handling and use.

11.4 Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

Candesartan Cilexetil:

Remarks : It is not a skin sensitiser in vivo.
Unlikely to cause skin sensitisation.

Hydrochlorothiazide:

Remarks : No information available.

Chronic toxicity

11.5 Germ cell mutagenicity

Not classified based on available information.

Components:

Candesartan Cilexetil:

Germ cell mutagenicity - Assessment : The substance is not considered to be genotoxic.

Hydrochlorothiazide:

Germ cell mutagenicity - Assessment : Some evidence of genotoxicity in vitro but not considered to present a mutagenic hazard to man.

11.6 Carcinogenicity

Not classified based on available information.

Components:

Candesartan Cilexetil:

Carcinogenicity - Assessment : The substance is not considered to be carcinogenic.

Version 3.0 Revision Date: 13.11.2019 SDS Number: 13231 Date of last issue: 19.01.2018
Date of first issue: 19.01.2018

Hydrochlorothiazide:

Carcinogenicity - Assessment : It is unlikely to present a carcinogenic hazard to man.

11.7 Reproductive toxicity

May damage fertility or the unborn child.

Components:**Candesartan Cilexetil:**

Reproductive toxicity - Assessment : Positive evidence of adverse effects on development from human epidemiological studies., Studies in animals have shown that high doses produce embryo/foetotoxic effects.

Hydrochlorothiazide:

Reproductive toxicity - Assessment : There is no evidence of reprotoxicity in animal tests., Substances with the ability to reduce blood pressure may adversely affect embryo-foetal development., The substance passes into breast milk

11.8 STOT - single exposure

Not classified based on available information.

Components:**Candesartan Cilexetil:**

Exposure routes : Oral
Remarks : May cause lowering of blood pressure.

Hydrochlorothiazide:

Exposure routes : Inhalation
Target Organs : Respiratory Tract
Remarks : May cause irritation to the upper respiratory tract.

Exposure routes : Oral
Remarks : May cause gastrointestinal irritation, nausea, dizziness and weakness.

11.9 STOT - repeated exposure

May cause damage to organs (Kidney, Blood) through prolonged or repeated exposure if swallowed.

Components:**Candesartan Cilexetil:**

Exposure routes : Oral
Target Organs : Kidney, Blood
Assessment : May cause damage to organs through prolonged or repeated exposure.
Remarks : These effects are derived from studies in animals.

Version 3.0 Revision Date: 13.11.2019 SDS Number: 13231 Date of last issue: 19.01.2018
Date of first issue: 19.01.2018

Hydrochlorothiazide:

Exposure routes : Oral
Target Organs : Kidney
Remarks : Ingestion studies in animals have shown that repeated doses produce adverse effects.

11.10 Aspiration toxicity

Not classified based on available information.

Components:**Candesartan Cilexetil:**

No data available

Hydrochlorothiazide:

No information available.

SECTION 12. ECOLOGICAL INFORMATION**Ecotoxicity****Components:****Candesartan Cilexetil:**

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 0.017 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 0.016 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants : ErC50 (Selenastrum capricornutum (green algae)): > 0.012 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

Toxicity to microorganisms : IC50 (activated sludge): 1,000 mg/l
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

Ecotoxicology Assessment

Chronic aquatic toxicity : May cause long lasting harmful effects to aquatic life.

Hydrochlorothiazide:

Toxicity to algae/aquatic plants : NOEC (Pseudokirchneriella subcapitata (green algae)): 100 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

EC50 (Chlorella vulgaris (Fresh water algae)): 34.35 mg/l
Exposure time: 72 h

Version 3.0 Revision Date: 13.11.2019 SDS Number: 13231 Date of last issue: 19.01.2018
Date of first issue: 19.01.2018

Method: OECD Test Guideline 201

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 10 mg/l
Exposure time: 30 d
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 100 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211

Persistence and degradability

Components:

Candesartan Cilexetil:

Biodegradability : Result: not rapidly degradable
Biodegradation: < 9 %
Exposure time: 28 d

Hydrochlorothiazide:

Biodegradability : Remarks: The substance is partially biodegradable in water.

Bioaccumulative potential

Components:

Candesartan Cilexetil:

Bioaccumulation : Remarks: The substance has high potential for bioaccumulation.

Hydrochlorothiazide:

Bioaccumulation : Remarks: The substance has low potential for bioaccumulation.

Mobility in soil

Components:

Candesartan Cilexetil:

Mobility : Remarks: Water solubility < 1 mg/l.

Distribution among environmental compartments : Remarks: No information available.

Hydrochlorothiazide:

Mobility : Remarks: The substance is soluble in water.
The substance has high mobility in soil.

Distribution among environmental compartments : Remarks: No information available.

Version 3.0 Revision Date: 13.11.2019 SDS Number: 13231 Date of last issue: 19.01.2018
Date of first issue: 19.01.2018

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS**Disposal methods**

- Waste from residues : Disposal should be in accordance with local, state or national legislation.
Waste, even small quantities, should never be poured down drains, sewers or water courses.
Dispose of contents/ container to an approved incineration plant.
- Contaminated packaging : Empty container will retain product residue. Observe all hazard precautions.
-

SECTION 14. TRANSPORT INFORMATION

Not classified as dangerous in the meaning of transport regulations.

SECTION 15. REGULATORY INFORMATION**Safety, health and environmental regulations/legislation specific for the substance or mixture**

In order to comply with legal duties it is necessary to consult local and national legislation.

Standard for the Uniform Scheduling of Medicines and Poisons : No poison schedule number allocated

Prohibition/Licensing Requirements : There is no applicable prohibition or notification/licensing requirements, including for carcinogens under Commonwealth, State or Territory legislation.

The components of this product are reported in the following inventories:

TCSI : Not listed

TSCA : Substance(s) not listed on TSCA inventory

AICS : Not listed

Version	Revision Date:	SDS Number:	Date of last issue: 19.01.2018
3.0	13.11.2019	13231	Date of first issue: 19.01.2018

DSL : This product contains the following components that are not on the Canadian DSL nor NDSL.
Candesartan Cilexetil

ENCS : Not listed

ISHL : Not listed

KECI : Not listed

IECSC : Not listed

CHINV : Not in compliance with the inventory

REACH : Not in compliance with the inventory

TRINV : Not in compliance with the inventory

SECTION 16. OTHER INFORMATION**Further information**

Revision Date : 13.11.2019

Other information : New significant SHE information:
3. Composition/information on ingredients
8. New Occupational Exposure Limit Value
Minor changes:
3
9
11
12
13
15
16

Date format : dd.mm.yyyy

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)
AU OEL : Australia. Workplace Exposure Standards for Airborne Contaminants.

ACGIH / TWA : 8-hour, time-weighted average
AU OEL / TWA : Exposure standard - time weighted average

AICS - Australian Inventory of Chemical Substances; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CHINV - China Inventory; CMR - Carcinogen, Mutagen or Reproductive Toxicant; COM - In-house occupational exposure limit; CPR - Controlled Products Regulations; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HYG -

SAFETY DATA SHEET



Version	Revision Date:	SDS Number:	Date of last issue: 19.01.2018
3.0	13.11.2019	13231	Date of first issue: 19.01.2018

Analytical method for occupational exposure monitoring; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; Sen - Capable of causing respiratory sensitization; Sk - Can be absorbed through skin, thus contributing to systemic effects; STEL - Short-term exposure limit 15-minutes time-weighted average; TLV - Threshold Limit Value (ACGIH); TLV-C - Threshold Limit Value Ceiling limit (ACGIH); TRINV - Turkey Inventory; TSCA - Toxic Substances Control Act (United States); TWA - Long-term exposure limit 8h time-weighted average; UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text.

AU / EN